Diagnosis and Treatment of Parasellar Lesions.

Federico Gatto, Luis G Perez-Rivas, Nicoleta Cristina Olarescu, Pati Khandeva, Konstantina Chachlaki, Giampaolo Trivellin, Manuel D Gahete, Thomas Cuny

Journal: Neuroendocrinology 2021;110(9-10):728-739

PMID: 32126547

Abstract

The parasellar region, located around the sella turcica, is an anatomically complex area representing a crossroads for important adjacent structures. Several lesions, including tumoral, inflammatory vascular, and infectious diseases may affect this area. Although invasive pituitary tumors are the most common neoplasms encountered within the parasellar region, other tumoral (and cystic) lesions can also be detected. Craniopharyngiomas, meningiomas, as well as Rathke's cleft cysts, chordomas, and ectopic pituitary tumors can primarily originate from the parasellar region. Except for hormone-producing ectopic pituitary tumors, signs and symptoms of these lesions are usually nonspecific, due to a mass effect on the surrounding anatomical structures (i.e., headache, visual defects), while a clinically relevant impairment of endocrine function (mainly anterior hypopituitarism and/or diabetes insipidus) can be present if the pituitary gland is displaced or compressed. Differential diagnosis of parasellar lesions mainly relies on magnetic resonance imaging, which should be interpreted by neuroradiologists skilled in base skull imaging. Neurosurgery is the main treatment, alone or in combination with radiotherapy. Of note, recent studies have identified gene mutations or signaling pathway modulators that represent potential candidates for the development of targeted therapies, particularly for craniopharyngiomas and meningiomas. In summary, parasellar lesions still represent a diagnostic and therapeutic challenge. A deeper knowledge of this complex anatomical site, the improvement of imaging tools, as well as novel insights into the pathophysiology of presenting lesions are strongly needed to improve the management of parasellar lesions.

© 2020 S. Karger AG, Basel.

Address: Endocrinology Unit, Department of Specialist Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.; Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.; Section of Specialized Endocrinology, Department of Endocrinology, Medical Clinic, Oslo University Hospital, and University of Oslo, Oslo, Norway.; Department of Medical Biochemistry, Oslo University, Oslo, Norway.; Endocrinology Research Center, Moscow, Russian Federation.; Inserm, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Jean-Pierre Aubert Research Centre, UMR-S 1172, Lille, France.; Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.; Maimónides Institute of Biomedical Research of Córdoba (IMIBIC), Córdoba, Spain.; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Reina Sofía University Hospital, Córdoba, Spain.; CIBER Pathophysiology of Obesity and Nutrition (CIBERobn), Córdoba, Spain.; Department of Endocrinology, Hospital La Conception, Aix Marseille University, APHM, INSERM, MMG, Marseille, France, [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.